Piper Sandler reiterates Overweight rating on Abbott Labs stock

Abbott Laboratories (ABT) presents a mixed outlook as Piper Sandler reiterates an Overweight rating, citing underappreciated growth catalysts in its diabetes business, notably a dual-analyte sensor expected in H1 2026 that could drive over 20% growth in 2026. This bullish sentiment, however, is tempered by Abbott's recent downward revision of its FY2025 revenue and EPS guidance due to challenges in its diagnostics segment, particularly China's volume-based procurement. Despite the lowered forecast, other firms like Jefferies and UBS maintain or upgrade positive ratings, highlighting robust performance in divisions such as MedTech, suggesting a nuanced but potentially resilient growth trajectory for the healthcare giant.

Analysis

Abbott Laboratories (ABT) presents a bifurcated outlook, characterized by near-term headwinds contrasting with a compelling long-term growth narrative. The primary bull case, articulated by Piper Sandler's Overweight rating and $150 price target, centers on underappreciated catalysts within the diabetes business. Specifically, the firm anticipates the H1 2026 launch of a dual-analyte glucose and ketone sensor will drive U.S. diabetes revenue growth "comfortably above the 20% level" in 2026, surpassing the current consensus of 18.1%. This view is supported by a valuation that Piper Sandler deems "very palatable" at 23.4 times 2026 consensus earnings. However, this optimism is tempered by Abbott's own recent guidance revision. The company lowered its full-year 2025 revenue growth forecast to a 7.5%-8.0% range and adjusted its EPS guidance to $5.10-$5.20, citing specific challenges in its diagnostics business due to China's volume-based procurement policies. Despite this guidance cut, other segments demonstrate resilience; the MedTech division, for instance, reported strong 12.2% organic growth in the second quarter. This has led to a split in analyst sentiment, with Citi and Mizuho lowering price targets while Jefferies upgraded the stock to Buy and UBS reiterated its Buy rating, reflecting a complex but potentially robust fundamental picture underpinned by 55 years of dividend payments and strong profitability metrics.

Key Decisions for Investors

• Investors should weigh the significant long-term growth potential from the diabetes pipeline, particularly the H1 2026 dual-analyte sensor, against the immediate headwinds from the lowered FY2025 guidance driven by diagnostics weakness in China.
• It is prudent to monitor the performance of the MedTech division, which reported strong 12.2% organic growth, as a key offset to the diagnostics segment's challenges, and watch for any updates on China's volume-based procurement policies.
• Given that multiple analysts remain bullish and view the valuation as reasonable, any stock price weakness resulting from the revised 2025 guidance could be considered a potential entry point for those with a long-term thesis centered on Abbott's innovation in diabetes and strength in MedTech.
• For income-focused investors, Abbott's 55-year track record of consistent dividend payments and relatively low price volatility provide a defensive cushion against the near-term uncertainty in its diagnostics business.